Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

News

Astra and Oxford report strong covid-19 vaccine

Damien Conover, CFA  |  24 Nov 2020Text size  Decrease  Increase  |  
Email to Friend

Following excellent data from Pfizer/BioNTech and Moderna, AstraZeneca (AZN) and partner Oxford reported favourable phase 3 data on covid-19 vaccine AZD1222. The vaccine has an efficacy rate of 90 per cent (low dose) and 62 per cent (full dose) with no major safety issues observed with the initial data cohort.

At the low dose, the efficacy looks fairly similar to competitor data, albeit slightly lower than the 94 to 95 per cent efficacy reported by others. We are increasing the vaccine’s probability of approval to 90 per cent, but given the firm’s commitment to pricing the vaccine at a non-profit level, we don’t expect any impact to Astra’s fair value estimate. However, the quick development of the vaccine reinforces the firm's innovative power and wide moat.

With the likely authorisation of a third vaccine, we expect global demand will be more easily satisfied over the next few years. Astra expects manufacturing capacity of up to 3 billion doses in 2021. Combined with almost 2 billion doses in total from Pfizer/BioNTech’s and Moderna’s vaccines, close to 3 billion people could be vaccinated (assuming 1.5 to 2 doses for each person).

Also, Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines, which may make Astra’s vaccine more appealing for less developed countries. We expect additional pivotal data from Johnson & Johnson, Sanofi, GlaxoSmithKline and many more vaccine manufacturers in 2021.

We continue to expect the pricing power of the vaccines to be low, especially with several competitors receiving government funding and stating a commitment to low vaccine pricing. However, we expect the very quick development of vaccines to enable the biopharma industry to gain goodwill with governments to help in discussions around any drug pricing reforms.

Morningstar healthcare strategist Karen Anderson delivered a presentation on 'The Race for the Covid-19 Vaccine' at the ' Morningstar Individual Investor Conference. Attendees can view the session here.

Damien Conover, CFA, is an associate director for Morningstar.

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'regulated financial advice' under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information, refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ). Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. The article is current as at date of publication.

Email To Friend